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Abstract 1 
 2 
Problem: Previous studies have suggested that immune perturbations during pregnancy can 3 
affect offspring type 1 diabetes (T1D) risk. We aimed to identify immunological markers that 4 
could predict offspring T1D or that were linked to T1D risk factors. 5 
Method of study: We quantified selected circulating immunological markers in mid-6 
pregnancy (interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-2 receptor α (IL-2Ra), IL-7 
2, -4, -5, -6, -10, -12p70, -13, -17A, granulocyte-macrophage colony stimulating factor (GM-8 
CSF), interferon (IFN)-γ, C-X-C motif chemokine 10 (CXCL10, interferon gamma-induced 9 
protein 10), C-C motif chemokine ligand (CCL) 2 (monocyte chemo-attractant protein 1), 10 
CCL3 (macrophage inflammatory protein (MIP) 1α), CCL4 (MIP-1β), tumor necrosis factor 11 
(TNF)) and cord blood plasma (neopterin and kynurenine/tryptophan ratio) in a case control-12 
study with 175 mother/child T1D cases (median age 5.8, range 0.7–13.0 years) and 552 13 
controls.  14 
Results: Pre-pregnancy obesity was positively associated with CCL4, CXCL10, 15 
kynurenine:tryptophan-ratio, and neopterin (p<0.01). The established T1D SNPs rs1159465 16 
(near IL2RA) and rs75352297 (near C-C chemokine receptor (CCR)2 and CCR3) were 17 
positively associated with soluble IL-2R and CCL4, respectively (p<0.01). There was a 18 
borderline association of CCL4 and offspring T1D risk, independent of maternal obesity and 19 
genotype. When grouping the immunological markers into M1, M2, Th1-, Th2-, or Th17 cell 20 
phenotypes, there was a borderline association (p = 0.02) with M1 phenotype and no 21 
association between M2-, Th1-, Th2-, or Th17 phenotypes. 22 
Conclusions: Increased mid-pregnancy CCL4 levels showed borderline associations with 23 
increased offspring T1D risk, which may indicate a link between environmental factors in 24 
pregnancy and offspring T1D risk.  25 
 26 
 27 
Keywords: Cord Blood, Cytokine, Human, Inflammatory markers, Norwegian Mother and 28 
Child Cohort Study, Pregnancy, Type 1 diabetes.   29 
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INTRODUCTION  1 
Type 1 diabetes (T1D) is one of the most prevalent chronic conditions in children, and is 2 
associated with increased morbidity and mortality 1. Mechanisms driving the rising incidence 3 
in most countries over past decades are unknown. The insulin-producing pancreatic β-cells 4 
are destroyed in an autoimmune process, triggered or driven by environmental and genetic 5 
factors increasing T1D susceptibility 2, which may operate already in fetal life 3.  6 
Cytokines are small proteins secreted by nearly all cell types to induce or modulate 7 
immune responses, and play important roles in a wide spectrum of pathologies. Cytokines 8 
are pleiotropic, and combinations of cytokines can dictate T-helper (Th) lymphocyte 9 
differentiation, or activate macrophages to pro- and anti-inflammatory states 4, 5, immune cell 10 
phenotypes that secrete distinct cytokine repertoires. Several T1D susceptibility genetic 11 
markers are in or near genes associated with cytokines or cytokine signaling 6. Cytokine-12 
driven immune responses are likely factors leading to β-cell destruction 7, and evidence is 13 
accumulating that circulating cytokines and related markers may predict T1D 8, 9.  14 
Cytokines are also involved in regulating normal pregnancy 10. Pregnant women with 15 
an inflammatory state involving cytokines such as infections, obesity 11 and higher age have 16 
a higher risk of offspring T1D 3, 12. Maternal cytokine secretion may affect the fetus for 17 
instance by inducing inflammation in, or crossing over, the placenta. Although some 18 
cytokines such as IL-6 can cross the placenta 13, most cytokines and inflammatory markers 19 
do not 13, 14. However, macrophage accumulation 15 and expression of toll like receptors in 20 
the placenta may amplify maternal inflammatory signals 16, and thus contribute to fetal 21 
disease risk 15. Previous studies have reported associations between maternal inflammatory 22 
markers and later health outcomes such as asthma and allergies 17, supporting that maternal 23 
inflammatory cytokines affect the offspring disease susceptibility later in life. To the best of 24 
our knowledge, there is only one small study published on maternal cytokines and offspring 25 
T1D risk. This study reported an association between increased early-pregnancy serum 26 
levels of IFN-γ and IL-1β and higher risk of offspring T1D 18; however, such associations 27 
need to be confirmed in larger studies.  28 
In order to address the knowledge gap regarding antenatal immune perturbations 29 
associated with offspring T1D risk, we aimed to study circulating immunological markers in 30 
maternal mid-pregnancy plasma (interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-2 31 
receptor α (IL-2Ra), IL-2, -4, -5, -6, -10, -12p70, -13, -17A, granulocyte-macrophage colony 32 
stimulating factor (GM-CSF), interferon (IFN)-γ, C-X-C motif chemokine 10 (CXCL10, 33 
interferon gamma-induced protein 10), C-C motif chemokine ligand (CCL) 2 (monocyte 34 
chemo-attractant protein 1), CCL3 (macrophage inflammatory protein (MIP) 1α), CCL4 (MIP-35 
1β), tumor necrosis factor (TNF)) and markers of IFN-γ activation in the child’s cord blood 36 
plasma (neopterin and the kynurenine to tryptophan ratio (KTR)), in a large case-control 37 
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study of offspring T1D, nested within one of the largest pregnancy cohorts in the world. The 1 
immune markers measured in maternal plasma were carefully selected, either due to prior 2 
association to T1D or celiac disease, to ensure representation of several types (Th1, Th2, 3 
Th17, and Treg) of immune responses, and believed to give reliable measurements given 4 
our sample handling. As cord blood plasma were not immediately separated and more 5 
frequently are affected by some degree of hemolysis we measured only neopterin and KTR 6 
in cord blood, two inflammatory markers believed to be relatively stable during sample 7 
handling and storage 19. A secondary aim was to assess associations of other suggested risk 8 
factors for type 1 diabetes, such as maternal obesity or genotype, and these circulating 9 
immunological markers.   10 
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METHODS 1 
Subjects and design 2 
We designed a nested case-control study in the Norwegian Mother and Child Cohort Study 3 
(MoBa) 20. MoBa recruited around 114,000 pregnancies from all over Norway during 1999-4 
2008, and children who developed T1D by February 5, 2014 were identified with a high 5 
degree of ascertainment by register linkage to the Norwegian Childhood Diabetes Registry 21. 6 
In all, 175 mother/child-pairs were included as T1D cases, and 552 mother/child-pairs from a 7 
random sample of the cohort with available blood samples were used as controls (Figure 8 
1).The randomly selected controls were largely similar to the whole MoBa cohort, with the 9 
exception of caesarean section and premature birth (15.2% vs 10.3% for caesarean section, 10 
and 6.2% vs 3.4% for premature birth, in the whole MoBa cohort vs picked random controls) 11 
22, conditions associated with missing blood samples in the MoBa Cohort. Characteristics of 12 
the study participants are given in Table 1. The establishment and data collection in MoBa 13 
has obtained a license from the Norwegian Data Inspectorate and approval from The 14 
Regional Committee for Medical Research Ethics, and the study was approved by The 15 
Regional Committee for Medical Research Ethics in South-Eastern Norway. Informed 16 
consent was obtained from all study participants.  17 
 18 
Sample handling 19 
Venous maternal blood were collected in EDTA tubes around pregnancy week 17-19, 20 
centrifuged and shipped overnight as plasma in ambient temperature to the Norwegian 21 
Institute of Public Health for storage at -80 °C. At delivery, umbilical cord vein blood were 22 
collected in EDTA tubes and shipped overnight in ambient temperature before centrifugation 23 
and storage at -80 °C until analysis. Cord blood plasma samples were visually assessed for 24 
degree of hemolysis and graded according to a four level color code 23. Maternal and cord 25 
blood samples were treated separately but equally, with personnel blinded to case/control 26 
status at all stages of sample handling and analysis.  27 
 28 
Laboratory assays  29 
We selected a limited set of cytokines based on prior association to either celiac disease or 30 
T1D, and to ensure representation of macrophage M1 and M2 phenotypes, and Th1, Th2, 31 
Th17, and Treg immune responses in the adaptive immune system. We avoided cytokines 32 
known or suspected to be present in undetectable concentrations in most healthy individuals, 33 
or to give unreliable measurements e.g. due to pre-analytical factors. In total we measured 34 
18 cytokines in maternal mid-pregnancy plasma using Bio-Plex protein array systems (Bio-35 
Rad, Hercules, CA), based on xMAP technology (Luminex, Austin, TX) as previously 36 
described 23 – interleukin (IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-2 receptor α (IL-2Ra), 37 
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IL-2, -4, -5, -6, -10, -12p70, -13, -17A, granulocyte-macrophage colony stimulating factor 1 
(GM-CSF), interferon (IFN)-γ, C-X-C motif chemokine 10 (CXCL10, interferon gamma-2 
induced protein 10), C-C motif chemokine ligand (CCL) 2 (monocyte chemo-attractant 3 
protein 1), CCL3 (macrophage inflammatory protein (MIP) 1α), CCL4 (MIP-1β), tumor 4 
necrosis factor (TNF)). Concentrations were calculated from a standard curve generated 5 
from standards provided by the assay manufacturer, and standard curves showing high 6 
sensitivity were selected to obtain similar lower limit of quantification (LLOQ) for all samples. 7 
The LLOQ ranged from 0.02 (IL-4) to 1.35 (CCL2) pg/mL, and corresponds to the lowest 8 
point of the standard curve yielding acceptable recovery. The inter-plate mean coefficient of 9 
variation (CV) across all dilutions ranged from 2.2% (CCL4) to 8.0% (IL-4). Further details of  10 
limits of quantification, inter- and intra-assay CVs  are given in previous publication 23. 11 
Umbilical-cord plasma concentrations of cotinine, neopterin, tryptophan and kynurenine were 12 
measured using a high-throughput liquid chromatography tandem mass-spectrometry at the 13 
Bevital laboratory (Bergen, Norway) 24, which have previously demonstrated acceptable pre-14 
analytical stability 25. The kynurenine/tryptophan ratio (KTR) was calculated by dividing the 15 
plasma concentration of kynurenine (nmol/L) by the concentration of tryptophan (µmol/L). A 16 
brief summary of the immune markers studied is given in the online repository of Mårild et al. 17 
23. 18 
 19 
Genotyping 20 
To account for established T1D susceptibility markers, participants were genotyped using a 21 
custom Illumina Golden Gate assay (Illumina, San Diego, CA). DNA extraction, genotyping 22 
methods and quality control procedures are described in detail in previous publication 23. 23 
Briefly, tag-SNPs (n = 144) on chromosome 6 were used to impute human leukocyte antigen 24 
(HLA) class II genotype 26, which was subsequently confirmed by classical HLA genotyping 25 
using allele specific PCR. Based on the previously established risk of T1D conferred by HLA 26 
genotype, we categorized genotypes into four groups: protective (carrying at least one copy 27 
of HLA DQA1*01:02-DQB1*06:02-DRB1*15:01 [DQ6-DR15]), increased risk (at least one 28 
copy of HLA DQA1*03-DQB1*03:02-DRB1*04 [DQ8-DR4] or DQA1*05:01-DQB1*02:01 29 
[DQ2-DR3], but not both haplotypes), high risk (heterozygous HLA DQ2-DR3/DQ8-DR4) or 30 
neutral (any other genotype). Established non-HLA T1D risk SNPs (n=51) were used to 31 
calculate a weighted additive genetic risk score (GRS, sum of risk alleles, weighted by their 32 
odds ratio (OR) for T1D reported in the literature, see Table S1 in the Online Repository). 33 
SNPs possibly associated with T1D and cytokine levels (n = 19, see Table S2 in the Online 34 
Repository) were tested against maternal immunological markers to assess if there were any 35 
specific genetic effects that should be included in the analysis.  36 
 37 
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Other variables 1 
Predefined variables potentially associated with the selected immunological markers and/or 2 
T1D were assessed as predictors for the immunological markers and included as covariates 3 
in the analysis of association between cytokines and T1D. Maternal smoking was assessed 4 
by self-reported questionnaires and concentration of umbilical cord plasma cotinine 24 (a 5 
biomarker for recent nicotine exposure, with children having ≥30 nmol/L assumed to be 6 
exposed to cigarette smoke during pregnancy irrespective of maternal self-reported data or 7 
missing information). Maternal infection frequency was assessed from self-reported 8 
questionnaires 23. Maternal age at delivery, parity, mode of delivery, child’s sex, birth weight, 9 
gestational age, month and calendar year of birth were collected from the Medical Birth 10 
Registry of Norway. Pre-pregnancy body mass index (BMI) was collected from both 11 
questionnaires and birth records, and obesity defined as BMI ≥30. Maternal T1D was 12 
collected from birth records, self-reported questionnaires and ICD-10 codes E10.0-E10.9 in 13 
the Norwegian Patient Registry. The distribution and categorization of these variables are 14 
shown in Table 1. The number of freeze thaw cycles (median 4, range 1 – 10 for maternal 15 
samples and median 3, range 1 – 9 for cord blood samples) had a relatively small, but 16 
statistically significant association with several cytokine concentrations, while degree of 17 
hemolysis in cord blood had a similarly small, but significant effect on neopterin 23. Maternal 18 
samples were spun down at the hospital then shipped overnight (median 1 day in transit, 19 
interquartile range (IQR) 1 – 2 days), while cord blood samples were shipped overnight then 20 
spun down at arrival (median 2 days in transit, IQR 1 – 3 days). Time in transit had a small, 21 
but significant effect on neopterin (fold difference 1.04, p <0.01), but we did not adjust for 22 
time in transit as the effect on the reported neopterin estimates was negligible. 23 
Statistical analysis 24 
A priori, we decided to base our primary analysis on a logistic regression model with 25 
T1D as the dependent variable and log2-transformed immunological markers as the 26 
explanatory variables. In a secondary analysis, we assessed possible deviation from linearity 27 
by testing the significance of a squared term of the explanatory variables and by categorical 28 
analysis. Based on the distribution of the immunological marker among controls, 29 
observations were categorized into tertiles. For markers where >33% of samples were below 30 
detection limit (IL-1β, IL-5, IL-12p70, IL-13, IFN-γ, CCL2, IL-2Rα, IL-17A), all the values 31 
below the detection limit were put in the lowest category and remaining levels were split in 32 
two groups at their median. Associations between predictors (maternal BMI, etc) and 33 
immunological markers in pregnancy and cord blood were assessed using linear regression 34 
with the log2-transformed immunological markers as the dependent variable. As 20 35 
immunological markers with some a priori evidence for association with T1D were tested, 36 
and cytokines tend to be positively correlated, Bonferroni correction for multiple testing would 37 
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be too conservative 27. We decided a priori to use 0.01 as our significance level in the 1 
analyses of each single immunological marker. 2 
The primary statistical test of the association between immunological markers and the 3 
offspring’s risk of T1D was a m-1 degree of freedom likelihood ratio test, where m equals the 4 
number of immunological markers (testing the complete null hypothesis that none of the 5 
markers were associated vs the alternative that at least one marker was associated with 6 
offspring T1D risk). Next, we used a likelihood ratio test to assess each of five subsets of 7 
immunological markers grouped as M1-, M2-, Th1-, Th2-, or Th17-pathway immunological 8 
markers (see Figure 2, Panel A for a simplified overview of pathways and their cytokines). 9 
We attempted to choose the most characteristic immunological markers for these subsets, 10 
and tried to avoid including immune markers which overlap between different subsets, thus 11 
not all immunological markers shown in the figure are included. Z-scores for each cytokine 12 
were calculated and used in the analysis of groups and the model including all cytokines. 13 
Further, we tested each single immunological marker as predictors of T1D, adjusted for 14 
maternal pre-pregnancy BMI, child’s HLA risk category, gestational age at delivery, mode of 15 
delivery and year of birth. We also assessed the impact of additional adjustment for maternal 16 
smoking during pregnancy, child’s non-HLA genetic risk score, maternal T1D, parity, freeze-17 
thaw cycles, and maternal age. Finally, we did an exploratory, hypothesis free analysis of 18 
cytokine patterns using k-means cluster analysis with 8 clusters on the log2-transformed 19 
maternal immunological markers. This assigned individuals to clusters (groups) with similar 20 
pattern across the 18 maternal immunological markers. We then compared the resulting 21 
clusters with respect to risk of offspring T1D in a logistic regression model.   22 
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RESULTS 1 
Established risk factors for T1D such as HLA class II and maternal T1D were more common 2 
in cases than in controls. Other characteristics were similar in cases and controls, except a 3 
higher proportion of maternal BMI above 30 among cases was observed (see Table I). The 4 
child’s median age at the end of follow-up was 8.6 (range 4.7 – 14.1) years in controls (see 5 
Table I), and the median age at diagnosis of T1D cases was 5.8 (range 0.7 – 13.0) years. 6 
The distribution of most immunological markers were approximately symmetrical after log2-7 
transformation (see Figure S1 in the Online Repository), although for around half of the 8 
markers a relatively large proportion of the participants had levels below the lower limit of 9 
quantification. There were strong positive pairwise correlations between immunological 10 
markers measured in mid-pregnancy maternal plasma (IL-1β, -1Ra, -2Ra, IL-2, -4, -5, -6, -10, 11 
-12p70, -13, -17A, GM-CSF, IFN-γ, CXCL10, CCL2, CCL3, CCL4, TNF), but not in markers 12 
measured in cord blood plasma (neopterin, KTR) (see Figure S2 in the Online Repository). 13 
Maternal mid-pregnancy IFN-γ was not associated with child’s neopterin or KTR. 14 
  15 
Predictors of immunological markers 16 
There was no significant seasonal variation for the level of any of the immunological markers, 17 
which implies seasonal infections do not influence levels of the immunological markers in a 18 
systematic fashion (See Figure S3 in the Online Repository). Maternal pre-pregnancy BMI 19 
was positively associated with maternal CCL4 and CXCL10 concentrations, as well as 20 
neopterin and KTR in cord blood, and had a borderline (p = 0.02) positive association with IL-21 
6 (see Table S3 and Figure S4 in the Online Repository). Notably, maternal BMI significantly 22 
predicted cord blood neopterin and KTR also after adjusting for the child’s birth weight (or 23 
ponderal index), while birthweight did not significantly predict cord blood concentrations of 24 
neopterin and KTR when adjusted for mothers BMI. Maternal levels of GM-CSF were lower 25 
in preterm deliveries and increased in mothers smoking during pregnancy. Carrying the T1D 26 
high-risk HLA genotype (heterozygous DQ2/DQ8) was associated with cord blood KTR (see 27 
Table S3 and Figure S4 in the Online Repository). The T1D non-HLA genetic risk score was 28 
not significantly associated with any of the immunological markers (see Table S3 in the 29 
Online Repository). Some maternal SNPs were associated with maternal mid-pregnancy 30 
cytokine levels at p<0.01, such as IL2RA SNP rs11594656 28 associated with soluble IL-2R, 31 
SNP rs3024505 (flanking IL10) associated with IL-10 and SNP rs75352297 (intergenic 32 
between C-C chemokine receptor (CCR)3 and CCR2) associated with CCL4 (see Table S2 33 
and Figure S4 in the Online Repository).  34 
 35 
Pregnancy and cord blood immunologic markers and risk of type 1 diabetes 36 
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The overall likelihood ratio test of the null hypothesis that none of the 20 immunological 1 
markers (IL-1β, -1Ra, -2Ra, IL-2, -4, -5, -6, -10, -12p70, -13, -17A, GM-CSF, IFN-γ, CXCL10, 2 
CCL2, CCL3, CCL4, TNF measured in maternal mid-pregnancy plasma, and neopterin and  3 
KTR measured in cord blood plasma at birth) were associated with T1D gave p = 0.17. The 4 
likelihood ratio tests of the macrophage M1 (CCL2, -3, -4, CXCL10, IFN-γ, GM-CSF) 5 
immunological markers gave p = 0.02, and the related M2 (IL4, IL13, IL1ra, IL10) 6 
immunological markers gave p = 0.13, while tests for the Th1, Th2 and Th17 groups gave 7 
p≥0.20 (see Figure 2B).  8 
Modelling each single immunological marker for association with T1D revealed no 9 
significant associations at the predefined 0.01 level after adjustment for covariates. Maternal 10 
mid-pregnancy plasma CCL4 showed a borderline association with T1D per doubling (p = 11 
0.04 per log2 increase, see Figure 3). Some immunological markers had an increased 12 
estimate and borderline association (ORs between 1.52 and 1.60, p-values between 0.02 13 
and 0.05) for the highest tertile category in the unadjusted analysis, such as maternal mid-14 
pregnancy plasma CCL2, IFN-γ, IL-4 and TNF, but these were all not significant after 15 
adjustment although their estimates were still increased (data not shown, and see Figure S5 16 
in the Online Repository). Adjustment for potential confounders had limited influence on most 17 
associations (see Figure S6 in the Online Repository). Likewise, adjusting for genotypes 18 
influencing immunological marker levels (e.g. adjusting for the rs75352297 genotype, which 19 
was significantly associated with CCL4 levels, when analyzing CCL4) did not influence our 20 
results to an appreciable degree (data not shown). Of note, the association between 21 
maternal obesity (BMI ≥30) and higher risk of offspring T1D (OR 2.28, 95% CI: 1.35 – 3.85, 22 
compared to BMI <25) remained significant after adjustment for immunological markers 23 
CCL4, CXCL10, neopterin and KTR (adjusted OR 1.99, 95% CI: 1.09 – 3.64).  24 
 25 
Posthoc analyses 26 
For immunological markers where there was a suggestive threshold association with T1D at 27 
the highest category (CCL4, IFN-γ, IL17a, IL2Rα, TNF, neopterin, see Figure S5 in the 28 
Online Repository), we explored associations using the 90th percentile as threshold. CCL4 29 
(OR 2.37, 95% CI 1.10 – 5.10, p = 0.03), neopterin (OR 0.40, 95% CI 0.16 – 0.99, p = 0.05) 30 
and IL17a (OR 2.16, 95% CI 1.03 – 4.54, p = 0.04) had suggestive associations with T1D 31 
development, but these must be interpreted with caution as the analyses were data-driven.  32 
As a sensitivity analysis, we adjusted for celiac disease (present in 21 cases and 5 33 
controls), which only slightly changed our estimates, with the largest change in the adjusted 34 
estimate per log2 increase of CCL4 and T1D risk (OR 1.52, 95% CI 1.08 – 2.13, p = 0.02)  35 
 Finally, k-means cluster analysis on the maternal cytokines reliably clustered 36 
individuals in eight groups based on similarity in pattern of cytokine concentrations. Visual 37 
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inspection of patterns of mean cytokine concentrations across the eight groups did not have 1 
any obvious correspondence to any of our a priori pathways (Th1, M1, etc.), and there was 2 
no clearly significant association between assigned group and risk of T1D, with the exception 3 
of cluster 8 which had a borderline protective association (OR 0.52, 95%CI 0.29 –0.92, p = 4 
0.03) when compared to Cluster 1. Cluster 1 was characterized by high levels of all 5 
cytokines, in particular IFN-γ and IL-17a, while cluster 8 was characterized by average and 6 
slightly higher than average level of all measured maternal immune markers except CXCL10, 7 
CCL4 and IL2-Rα, which were slightly lower than average (Figure S7).   8 
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Discussion 1 
While none of the immunological markers were significantly associated with 2 
childhood-onset T1D according to our predetermined 0.01 level, there were borderline 3 
significant associations of increased maternal CCL4 with childhood T1D risk. Another finding 4 
was that maternal pre-pregnancy obesity was associated with higher concentrations of 5 
CCL4, CXCL10, neopterin and KTR, and remained associated with T1D also after 6 
adjustment for these immunological markers. 7 
Interestingly, a common feature of CCL4 and other cytokines with a possible 8 
association to T1D risk in the offspring, such as CCL2 and IFN-γ, is activation of pro-9 
inflammatory macrophages. In response to tissue damage and pathogen invasion, CD4+ T-10 
cells are differentiated to Th1, which main product is IFN-γ. IFN-γ stimulates macrophages to 11 
become pro-inflammatory 29, designated M1 macrophages known to secrete chemokines like 12 
CCL4 and -2 30 , as opposed to M2 macrophages that are anti-inflammatory and a result of 13 
stimulation by IL-4 and -10 and with a different secretory repertoire. Pregnancy is dependent 14 
on a finely tuned regulation of immune responses, and after the first trimester the maternal 15 
circulating cytokine pattern skews towards a type 2 polarization 31, while IFN-γ levels are 16 
depressed throughout the whole pregnancy 32. Similarly, decidual macrophages exhibit a 17 
mixed M1/M2 phenotype that can secrete CCL4 33 during the first half of the pregnancy, 18 
before switching to a M2 phenotype in the latter part of pregnancy 34. Deviations in maternal 19 
immune status in pregnancy have been linked with immune pathologies. Maternal exposure 20 
to Th2-inducing environmental irritants enhance offspring allergic responses 35, and maternal 21 
IL-17a promotes autism-like behavior abnormalities in offspring in mice 36. Lindehammer and 22 
co-workers found an association between increased IFN-γ in maternal sera and T1D in the 23 
offspring 18. 37-39Our observation of an association between M1 cytokine levels in mothers 24 
and offspring T1D risk supports that a skewing towards type 1 immune responses in mothers 25 
could influence offspring T1D risk. 3839. The underlying mechanism behind the potential 26 
association of increased maternal plasma levels of M1 cytokines, in particular CCL4, and 27 
offspring T1D remains speculative. CCL4 is a CC chemokine that has affinity for the C-C 28 
chemokine receptor type 5 (CCR5), and is a chemoattractant for, and activates, several 29 
immune cells 40. In the pregnant woman, there are several sources for plasma cytokines, 30 
including circulating leukocytes and the placenta. Whether the cytokine pattern observed 31 
during pregnancy in the maternal circulation reflect the fetal circulation is uncertain, but 32 
maternal inflammation has been associated with cord blood inflammation 41. The crossing of 33 
these cytokines over the placenta has not been studied in detail, although CCL4 are 34 
expressed at the maternal-fetal interface 42. CCL2 and CCL4 are found in cord blood, with 35 
higher levels in preterm infants 43, so macrophages with phenotypes similar to M1 36 
macrophages could be present in fetal life. Indeed, macrophages are involved in fetal 37 
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development, and recent evidence suggests that the majority of tissue macrophages in 1 
adults, at least in mice, are of fetal origin 44. It is therefore tempting to speculate that the 2 
maternal immunological state can program fetal macrophages to a M1 phenotype causing a 3 
susceptibility to T1D development in the offspring. Such programming could be a result of 4 
maternal IFN-γ crossing the placenta or affecting fetal immune cells at the maternal-fetal 5 
interface, or involve a higher level of regulation, such has epigenetic factors, but these 6 
possibilities need to be assessed in further studies and are currently unclear.  7 
Our findings are in accordance with studies in T1D patients which demonstrate 8 
elevated circulating levels of CCL4 45, 46, CCL2 7, 45 and IFN-γ 8. High-risk individuals without 9 
T1D had an elevated level of CCL4 9, 47 and IFN-γ 8, and IFN-γ levels were higher in high-risk 10 
persons than in patients with recent onset T1D48. In experimental studies using mouse 11 
models, these cytokines are essential in initiating pancreatic inflammation. Overexpression of 12 
IFN-γ in β-cells has been shown to lead to destruction of β-cells 49, and expression of CCL2 13 
by β-cells leads to accumulation of macrophages in the islets 50. Intriguingly, pancreatic 14 
macrophages are thought be essential in T1D pathogenesis 51, 52, being the first cells to 15 
infiltrate Langerhans islets 53. Thus, previous studies support a mechanistic role for M1-16 
associated cytokines in orchestrating inflammation and injury early T1D development, 17 
although experimental studies are contradictory regarding the role of CCL4 54.  18 
Many of our findings are coherent with earlier literature and supports that obesity and 19 
smoking are inflammatory states. We demonstrated an association between increased GM-20 
CSF levels and maternal smoking status, a link supported by in vitro studies 55. Individuals 21 
with obesity in general have been shown to have higher circulating levels of CCL4 56, 22 
CXCL10 57, neopterin 58 and KTR 59, in line with our results in pregnant women. We also 23 
found an association of maternal IL-6 with BMI (fold difference 1.05, p = 0.02), which has 24 
been contradictory in previous studies 60. Obesity is associated with increased M1 25 
polarization 37, and maternal obesity is a risk factor for offspring diabetes 12. Although 26 
inflammation could be a potential link between maternal obesity and offspring T1D risk, the 27 
fact that the association between maternal obesity and offspring T1D was not materially 28 
changed after adjustment for immunological markers suggest that the immunological 29 
markers measured in our study did not explain the link between maternal obesity and 30 
offspring T1D. Furthermore, we found significant associations between the established T1D 31 
susceptibility SNP rs11594656 (near IL2RA) and soluble IL-2R levels, supporting similar 32 
observations in non-pregnant adults 28, 61, and between rs3024505, flanking the IL10 locus 33 
and maternal circulating IL-10, consistent with  a previous study 62. The association between 34 
rs75352297 (a SNP near CCR2 and CCR3), and CCL4 levels is somewhat surprising as the 35 
main receptor for CCL4 is CCR5. However, rs75352297 is in linkage disequilibrium with 36 
rs6808835, which has been reported to influence CCL4 levels in cerebrospinal fluid 63, and is 37 
15 
 
 
in the CCR-Like 2 gene which is close to CCR5. Thus, rs75352297 might be a marker for 1 
haplotypes which could influence CCL4 levels, although the specific mechanisms are 2 
unknown.   3 
Strengths of the study include the prospective design, the large number of samples 4 
tested and prospectively collected information on covariates that allowed us to statistically 5 
adjust for a number of relevant factors. Weaknesses of the study include suboptimal sample 6 
handling. In cord samples, marker concentrations could be influenced by a longer period 7 
before separation, and an increase in neopterin levels has been reported in similar conditions 8 
64. However, because of our prospective design, any influence of suboptimal sample handling 9 
should not depend on outcome (T1D case status) and is therefore not likely to create any 10 
spurious association. On the other hand, we cannot exclude type II errors.  Some samples 11 
underwent several freeze-thaw cycles, but our data indicate that the measured 12 
concentrations are only slightly changed by repeated freeze-thaw cycles. We cannot exclude 13 
the role of processes taking place in other periods of the pregnancy, local effects by 14 
cytokines that are not secreted systemically, or effects exerted by cytokines restricted to the 15 
fetal circulation. Reports of links between cytokine levels in newborns and T1D risk 65 16 
indicate that the cytokine patterns in the fetal circulation may hide additional cues to the 17 
evolvement of T1D predisposition. Although we attempted to limit the number of 18 
immunological markers to test, we cannot exclude multiple testing problems.  19 
In conclusion, increased mid-pregnancy maternal levels of cytokines related to 20 
activated M1 macrophages, in particular CCL4, might influence offspring T1D risk, although 21 
more studies are needed to confirm this association. 22 
 23 
  24 
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Table I: Characteristics of the study  
participants 
 Controls (n= 552) Cases (n =175) 
Median age (range) at end of follow-up (years) 8.6 (4.7-14.1) 9.8 (5.0-13.3)* 
Female sex 272 (49.3%) 87 (49.7%) 
Maternal type 1 diabetes 0 (0.0%) 7 (4.0%) 
Preterm birth 19 (3.4%) 10 (5.7%) 
Missing data 1 (0.2%) 3 (1.7%) 
Birthweight (in grams)   
<2500 g 8 (1.4%) 7 (4.0%) 
2500-3500 g 231 (41.9%) 66 (37.7%) 
>3500-4500 g 285 (51.6%) 94 (53.7%) 
>4500 g 28 (5.1%) 8 (4.6%) 
Parity   
No earlier births 240 (43.5%) 86 (49.1%) 
One 203 (36.8%) 53 (30.3%) 
Two or more 109 (19.8%) 36 (20.6%) 
Maternal age (years)   
<25 70 (12.7%) 16 (9.1%) 
25-35 390 (70.6%) 134 (76.6%) 
 >35 92 (16.7%) 25 (14.3%) 
Self-reported maternal infections in pregnancy   
None 191 (34.6%) 62 (35.4%) 
One 172 (31.2%) 54 (30.9%) 
Two or more 189 (34.2%) 59 (33.7%) 
Maternal smoking during pregnancy   
Not during pregnancy 388 (70.3%) 127 (72.6%) 
Stopped smoking prior to pregnancy 14 (2.5%) 5 (2.9%) 
Smoked at any time during pregnancy 119 (21.6%) 37 (21.1%) 
Missing data 31 (5.6%) 6 (3.4%) 
Maternal pre-pregnancy BMI (kg/m2)   
<25 309 (55.6%) 76 (43.4%) 
25-30 136 (24.6%) 55 (31.4%) 
>30 50 (9.1%) 28 (16.0%) 
Missing data 57 (10.3%) 16 (9.1%) 
Childs HLA genotype and genetic risk score   
Protective (DQ6) 171 (31.0%) 3 (1.7%) 
Baseline (any other HLA not mentioned) 112 (20.3%) 5 (2.9%) 
Increased risk (≥1 copy of either DQ8 or DQ2.5) 210 (38.0%) 94 (53.7%) 
High risk (DQ8/DQ2.5 heterozygote) 31 (5.6%) 72 (41.1%) 
Missing HLA genotype 28 (5.1%) 1 (0.6%) 
T1D non-HLA GRS† (median, IQR) 61.2, 47.3 – 75.2 63.2, 51.0 – 76.7 
Number of freeze-thaw cycles (median, range) ‡   
Cord blood samples 3, 1 – 9 3, 1 – 7 
Mid-pregnancy samples 4, 1– 10 4, 1 – 9 
Caesarean section§ 57 (10.3%) 34 (19.4%) 
 1 
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* The median age at diagnosis of T1D cases was 5.8 (range 0.7 – 13.0) years 1 
† The genetic risk score was calculated as the number of risk alleles of SNPs associated 2 
with T1D, weighted by their ORs (see Supplemental Table 1).  3 
‡ Categorized as 1, 2, 3, 4, 5, 6.3 for cord blood samples and 1, 2, 3, 4, 5, 6, 7.5 for maternal 4 
mid-pregnancy samples. To avoid small groups, all freeze-thaw cycles >5 in cord blood and 5 
>6 in maternal mid-pregnancy samples were categorized together at their mean value (6.3 6 
and 7.5 for cord blood and maternal mid-pregnancy samples, respectively). 7 
§ includes unknown (n = 1), emergency (n = 53) and elective (n = 37) caesarean section 8 
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Figure 1: Flow chart of the participants 1 
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Figure 2: Simplified overview of the stimulation by, and secretion of, the selected 1 
maternal immunological markers.  2 
*IL2-Rα chosen as a better marker of IL-2 activity than IL-2 itself  3 
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Figure 3: Immunological markers and their association with offspring T1D per log2 1 
increase. A log2 increase represents a doubling. These results are adjusted for maternal 2 
pre-pregnancy BMI, child’s T1D HLA risk category, gestational age at delivery, mode of 3 
delivery and year of birth. Neopterin is additionally adjusted for degree of hemolysis in cord 4 
blood.  5 
 6 
adjusted Odds Ratio: aOR; 95% CI confidence interval: 95% CI  7 
